Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma DOI Open Access
Katja Seipel,

Lynn Benninger,

Ulrike Bacher

и другие.

Therapeutics, Год журнала: 2024, Номер 1(2), С. 95 - 105

Опубликована: Ноя. 29, 2024

Background/Objectives: Mantle cell lymphoma (MCL) represents a rare B-cell subtype with rather high relapse rates. Somatic mutations in the PPM1D gene were shown to be associated adverse outcomes patients diffuse large (DLBCL) who received CD19 CAR-T-cell therapy tisa-cel, which may also apply mantle receiving brexu-cel CAR-T-cells. Methods: In this study, we determined prevalence of peripheral blood cells MCL before infusion and analyzed impact low-frequency on efficacy safety aspects treatment first 16 r/r enrolled at Inselspital Bern. Results: The was 25%, variant allele frequencies (VAF) 0.011 0.099. Clinical response mutated (PPM1Dmut) vs. wild-type (PPM1Dwt) groups median progression-free survival 1 versus 32 months (p = 0.07) overall 1.5 27 0.001). Conclusions: Our data suggest that predict inferior treated therapy.

Язык: Английский

Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain DOI Creative Commons
Jay Kumar, Dalibor Košek, Stewart R. Durell

и другие.

Journal of Biological Chemistry, Год журнала: 2024, Номер 300(8), С. 107561 - 107561

Опубликована: Июль 11, 2024

Язык: Английский

Процитировано

2
Molecular Dynamics Simulations in Drug Discovery DOI
Onur Serçinoğlu, Xavier Chee Wezen, Ayesha Fatima

и другие.

Elsevier eBooks, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

2
Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma DOI Open Access
Katja Seipel,

Lynn Benninger,

Ulrike Bacher

и другие.

Therapeutics, Год журнала: 2024, Номер 1(2), С. 95 - 105

Опубликована: Ноя. 29, 2024

Background/Objectives: Mantle cell lymphoma (MCL) represents a rare B-cell subtype with rather high relapse rates. Somatic mutations in the PPM1D gene were shown to be associated adverse outcomes patients diffuse large (DLBCL) who received CD19 CAR-T-cell therapy tisa-cel, which may also apply mantle receiving brexu-cel CAR-T-cells. Methods: In this study, we determined prevalence of peripheral blood cells MCL before infusion and analyzed impact low-frequency on efficacy safety aspects treatment first 16 r/r enrolled at Inselspital Bern. Results: The was 25%, variant allele frequencies (VAF) 0.011 0.099. Clinical response mutated (PPM1Dmut) vs. wild-type (PPM1Dwt) groups median progression-free survival 1 versus 32 months (p = 0.07) overall 1.5 27 0.001). Conclusions: Our data suggest that predict inferior treated therapy.

Язык: Английский

Процитировано

0